CONCORDBIO - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.7
| Stock Code | CONCORDBIO | Market Cap | 13,814 Cr. | Current Price | 1,315 ₹ | High / Low | 2,039 ₹ |
| Stock P/E | 52.0 | Book Value | 193 ₹ | Dividend Yield | 0.81 % | ROCE | 18.5 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 1,200 ₹ | DMA 200 | 1,310 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.36 % | PAT Qtr | 90.0 Cr. | PAT Prev Qtr | 70.2 Cr. |
| RSI | 60.4 | MACD | 59.5 | Volume | 2,94,542 | Avg Vol 1Wk | 2,76,577 |
| Low price | 987 ₹ | High price | 2,039 ₹ | PEG Ratio | 12.6 | Debt to equity | 0.00 |
| 52w Index | 31.2 % | Qtr Profit Var | -36.6 % | EPS | 25.2 ₹ | Industry PE | 32.5 |
CONCORDBIO shows moderate fundamentals with decent ROCE and ROE, zero debt, and improving PAT compared to the previous quarter. However, the high P/E ratio relative to industry, weak PEG ratio, and significant quarterly profit variation raise concerns. Technically, the stock is trading close to its 200 DMA, with RSI at 60.4 and MACD positive, suggesting mild bullish momentum. It is a cautious candidate for swing trading.
💡 Optimal Entry Price: Around 1,250–1,280 ₹ (near support levels close to DMA 50).
📈 Exit Strategy: If already holding, consider booking profits near 1,380–1,420 ₹ or exit if price falls below 1,200 ₹ (DMA 50 support).
✅ Positive
- 📈 ROCE at 18.5% and ROE at 13.9% show moderate efficiency.
- 💰 Zero debt-to-equity ratio indicates strong financial stability.
- 📊 PAT improved from 70.2 Cr. to 90 Cr. quarter-on-quarter.
- 📉 Price trading above DMA 50 and near DMA 200, showing technical support.
⚠️ Limitation
- 📉 High P/E ratio of 52 compared to industry average of 32.5.
- 📉 Very weak PEG ratio at 12.6, suggesting poor valuation relative to growth.
- 📉 Quarterly profit variation (-36.6%) indicates earnings volatility.
📰 Company Negative News
- 📉 Decline in DII holding (-0.36%) shows reduced domestic institutional confidence.
- 📉 EPS at 25.2 ₹ is modest relative to high valuation.
🌟 Company Positive News
- 📈 Increase in FII holding (+0.21%) signals foreign investor interest.
- 📊 PAT growth quarter-on-quarter shows operational improvement.
🏭 Industry
- 📊 Industry P/E at 32.5, significantly lower than CONCORDBIO, suggesting sector is moderately valued.
- 📈 Biopharma industry remains growth-oriented but faces valuation pressures.
📌 Conclusion
CONCORDBIO presents a mixed case for swing trading. While debt-free status and recent PAT improvement are positives, high valuation and earnings volatility limit upside potential. Entry is favorable near 1,250–1,280 ₹, with profit booking advised around 1,380–1,420 ₹. Risk management is essential due to valuation concerns.